Diabetes Care, Vol 20, Issue 11 1697-1701, Copyright © 1997 by American Diabetes Association

ARTICLES

Effects of a quick-release form of bromocriptine (Ergoset) on fasting and postprandial plasma glucose, insulin, lipid, and lipoprotein concentrations in obese nondiabetic hyperinsulinemic women

V Kamath, CN Jones, JC Yip, BB Varasteh, AH Cincotta, GM Reaven and YD Chen
Department of Medicine, Stanford University, School of Medicine, CA 94305-5013, USA.

OBJECTIVE: To assess the effect on various aspects of carbohydrate and lipid metabolism of administering a quick-release formulation of bromocriptine (Ergoset) to obese, nondiabetic, hyperinsulinemic women. RESEARCH DESIGN AND METHODS: Hourly concentrations of prolactin, glucose, insulin, free fatty acid (FFA), and triglyceride were measured for 24 h before and after approximately 8 weeks of treatment with Ergoset. In addition, fasting lipid and lipoprotein concentrations and the steady-state plasma glucose (SSPG) concentration in response to a continuous infusion of somatostatin, insulin, and glucose were determined before and after Ergoset administration. RESULTS: Circulating prolactin concentrations were dramatically decreased (P < 0.001) following treatment, associated with a significant fall (P < 0.05) in 24-h-long plasma glucose, FFA, and triglyceride concentrations. Neither circulating plasma insulin concentrations nor the ability of insulin to mediate glucose disposal changed with treatment. Finally, fasting total cholesterol fell (P < 0.05) and the ratio of total to HDL cholesterol decreased (P = 0.06) in association with Ergoset treatment. CONCLUSIONS: The fact that significant metabolic improvement was seen in the obese nondiabetic hyperinsulinemic women studied suggests that Ergoset could be of therapeutic benefit in clinical conditions of hyperglycemia and/or dyslipidemia.
CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				G. A. Bray and F. L. Greenway Pharmacological Treatment of the Overweight Patient Pharmacol. Rev., June 1, 2007; 59(2): 151 - 184. [Full Text] [PDF]

				P. Kok, F. Roelfsema, M. Frolich, J. van Pelt, M. P. M. Stokkel, A. E. Meinders, and H. Pijl Activation of dopamine D2 receptors simultaneously ameliorates various metabolic features of obese women Am J Physiol Endocrinol Metab, November 1, 2006; 291(5): E1038 - E1043. [Abstract] [Full Text] [PDF]

				M. M. Hagan, P. J. Havel, R. J. Seeley, S. C. Woods, N. N. Ekhator, D. G. Baker, K. K. Hill, M. D. Wortman, A. H. Miller, R. L. Gingerich, et al. Cerebrospinal Fluid and Plasma Leptin Measurements: Covariability with Dopamine and Cortisol in Fasting Humans J. Clin. Endocrinol. Metab., October 1, 1999; 84(10): 3579 - 3585. [Abstract] [Full Text] [PDF]